French assess extracorporeal photopheresis against element of controversy
This article was originally published in Clinica
Executive Summary
The health technology assessment unit within the French Supreme Health Authority, Haute Autorité de Santé (HAS), is carrying out an assessment of extracorporeal photopheresis (ECP), a leukapheresis-based immunomodulatory therapy for the treatment of cutaneous T-cell lymphoma (CTCL). One of the outcomes of this work is expected to be the reimbursement in France, under certain conditions, of this therapy.